SCHEDULE 13D: Biotechnology Value Fund Group Discloses Nearly 20% Stake in ESSA Pharma, Citing Undervaluation

A group of investment funds led by Biotechnology Value Fund L.P. has disclosed a significant 19.7% beneficial ownership stake in ESSA Pharma Inc., stating the shares were acquired due to their belief in the company's undervaluation and attractive investment opportunity.

Summary

• A group of ten reporting persons, including Biotechnology Value Fund L.P. and its affiliates (collectively, the 'Reporting Persons'), have jointly filed a Schedule 13D, disclosing their beneficial ownership in ESSA Pharma Inc. Common Shares.
• As of April 8, 2025, the Reporting Persons collectively beneficially own 8,748,629 Common Shares of ESSA Pharma Inc., representing approximately 19.7% of the company's outstanding shares.
• This ownership includes direct holdings by Biotechnology Value Fund L.P. (4,712,590 shares, 10.6%), Biotechnology Value Fund II L.P. (3,491,779 shares, 7.9%), Biotechnology Value Trading Fund OS LP (357,472 shares, 0.8%), and 186,788 shares held in a Partners Managed Account.
• The Reporting Persons also hold 2,920,000 pre-funded warrants, exercisable for an aggregate of 2,920,000 Common Shares at a nominal exercise price of $0.0001 per share, though their exercise is currently limited by a 9.99% beneficial ownership cap.
• The aggregate purchase price for the shares owned directly by BVF was approximately $19,751,549, for BVF2 was approximately $14,105,174, for Trading Fund OS was approximately $1,373,303, and for the Partners Managed Account was approximately $1,292,828.
• The shares were acquired using working capital, which may include margin loans.
• The Reporting Persons acquired the securities believing they were undervalued and represented an attractive investment opportunity.

Sentiment

Score: 7

Explanation: The sentiment is positive from the perspective of the acquiring investor group, as they explicitly state their belief that the securities were 'undervalued and represented an attractive investment opportunity.' This indicates confidence in the company's future prospects from a significant shareholder.

Positives

• The Reporting Persons believe ESSA Pharma Inc. securities were undervalued at the time of purchase, indicating potential upside.
• The significant stake (19.7%) by a specialized biotechnology investment group signals strong conviction in the company's prospects.
• The Reporting Persons may engage with management and the Board, potentially leading to strategic improvements or value creation initiatives.

Negatives

• The existence of pre-funded warrants that cannot be fully exercised due to a beneficial ownership limitation (9.99%) indicates a potential restriction on immediate full conversion of their investment instruments.

Risks

• The Reporting Persons may increase or decrease their position, which could introduce volatility to the stock price.
• Potential for activist engagement, including proposals for changes to capitalization, ownership structure, or Board composition, which could lead to uncertainty or conflict.
• The investment strategy includes the possibility of short selling or hedging, which could negatively impact the stock price.

Future Outlook

The Reporting Persons intend to continuously review their investment in ESSA Pharma Inc. and may adjust their position by purchasing additional shares, selling existing shares, or engaging in short selling or hedging transactions. They also reserve the right to engage in communications with the company's management and Board, discuss with other stockholders, and propose changes to the company's capitalization, ownership structure, Board composition, or operations.

Management Comments

• "The Reporting Persons purchased the securities reported owned herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity."

Industry Context

This filing indicates a significant investment by a specialized biotechnology fund in ESSA Pharma Inc., a company operating in the biotech sector. Such a substantial stake, particularly by a fund known for active engagement, suggests a belief in the company's underlying value or potential for strategic shifts within the competitive biotechnology landscape. It could signal an increased focus on the company's pipeline, market position, or corporate governance, potentially influencing broader investor sentiment towards similar small-to-mid cap biotech firms.

Corporate Governance

Related Party Transactions

• The filing details the relationships among the Reporting Persons (e.g., general partners, investment managers, sole officers/directors) and their respective authorities over the investment funds and managed accounts, which govern their joint beneficial ownership and filing obligations.

Stakeholder Impact

• **Shareholders**: Increased institutional ownership and potential for activist engagement could lead to strategic changes aimed at enhancing shareholder value, but also potential for volatility if the Reporting Persons significantly alter their stake.
• **Management/Board**: Potential for increased scrutiny and direct engagement from a significant shareholder, possibly leading to changes in corporate strategy or governance.
• **Employees**: Potential for operational changes could indirectly impact employees, depending on the nature of any proposed strategic shifts.

Next Steps

• The Reporting Persons will continue to review their investment in ESSA Pharma Inc. on an ongoing basis.
• They may increase or decrease their position in the Issuer through open market purchases, private transactions, or other means.
• They may engage in communications with ESSA Pharma Inc.'s management and Board of Directors.
• They may engage in discussions with other stockholders of ESSA Pharma Inc. regarding their investment.
• They may make proposals to ESSA Pharma Inc. concerning changes to its capitalization, ownership structure, Board structure (including composition), or operations.
• They may engage in short selling or hedging transactions with respect to the shares.

Key Dates

Recommendation

Keywords

ESSA Pharma Inc., Biotechnology Value Fund, Schedule 13D, Beneficial Ownership, Investment Stake, Undervalued Securities, Activist Investor, Common Shares, Pre-Funded Warrants, Biotech, Pharmaceuticals